Physician profile
Dean R Wright
NPI 1578511226
$12,494.81
in general payments reported to CMS, 2019-2025
59 companies · $2,366 in 2025
The $2,366 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,688 · 2020: $1,764 · 2021: $1,924 · 2022: $1,424 · 2023: $1,554 · 2024: $1,774 · 2025: $2,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,682 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,682.19 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,848.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,662.94 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,631.07 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,090.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $653.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $588.35 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $440.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.11 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $338.19 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $287.27 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $255.77 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $230.50 | 2022-2023 | Quviviq |
| Abbott Laboratories | $218.12 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $191.73 | 2020 | |
| Phathom Pharmaceuticals, INC. | $178.10 | 2024-2025 | Voquezna |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.